Table 1.
Characteristics of included studies
| Ref. | Location | Type of malignancy included | Duration of study | Total No. of pts with HM included | Matched COVID-19 control | No. of lymphoma pts | No. of NHL pts | No. of HL pts | Mortality rate attributed to COVID-19 (Global) | Mortality rate attributed to COVID-19 (Lymphoma) | Mortality rate attributed to COVID-19 (NHL) | Mortality rate attributed to COVID-19 (HL) |
| Cancer studies including lymphoma pts | ||||||||||||
| Rüthrich et al[36], 2020 | Europe | All | 5 mo | 435 | 2636 | 76 | 71 | 5 | 96/435 (22%) | 20/76 (26%) | NR | NR |
| Lee et al[12], 2020 | UK | All | 1 mo | 1044 | 282878 | 79 | NR | NR | 319/1044 (31%) | 25/79 (31%) | NR | NR |
| Tian et al[50], 2020 | China | All | 9 wk | 232 | 519 | 6 | 6 | 0 | 46/232 (20%) | 2/6 (33%) | 2/6 (33%) | NR |
| HM studies including lymphoma pts | ||||||||||||
| Aries et al[34], 2020 | UK | HM | 2 mo | 35 | No | 8 | 8 | 0 | 14/35 (40%) | NR | NR | / |
| Biernat et al[51], 2020 | Poland | HM | 1 mo | 10 | No | 3 | 3 | 0 | 7/10 (70%) | NR | NR | / |
| Booth et al[52], 2020 | UK | HM | 2 mo | 66 | No | 15 | 15 | 0 | 34/66 (52%) | 6/15 (40%) | 6/15 (40%) | / |
| Cattaneo et al[42], 2021 | Italy | HM | 1 mo | 102 | 101 | 42 | 40 | 2 | 40/102 (39%) | 17/42 (40%) | 16/40 (40%) | 1/2 (50%) |
| Fox et al[53], 2020 | UK | HM | 1 mo | 55 | No | 17 | 17 | 0 | 19/55 (35%) | 7/17 (41%) | 7/17 (41%) | / |
| Garcìa-Suàrez et al[54], 2020 | Spain | HM | 8 wk | 697 | No | 220 | 187 | 33 | 230/697 (33%) | 68/220 (31%) | 59/187 (32%) | 9/33 (27%) |
| Infante et al[55], 2020 | Spain | HM | 1 mo | 41 | No | 15 | 14 | 1 | 15/41 (37%) | NR | NR | NR |
| Lattenist et al[56], 2021 | Belgium | HM | 2 mo | 12 | No | 2 | 2 | 0 | 6/12 (50%) | 2/2 (100%) | 2/2 (100%) | / |
| Malard et al[57], 2020 | France | HM | 1 mo | 25 | No | 7 | 7 | 0 | 10/25 (40%) | 0/7 (0%) | 0/7 (0%) | / |
| Martín-Moro et al[33], 2020 | Spain | HM | 5 wk | 34 | No | 6 | 5 | 1 | 11/34 (32%) | 0/6 (0%) | 0/5 (0%) | 0/1 (0%) |
| Mehta et al[32], 2020 | USA | HM | 3 wk | 54 | No | 20 | 15 | 5 | 20/54 (37%) | 8/20 (40%) | 5/15 (33%) | 3/5 (60%) |
| Passamonti et al[37], 2020 | Italy | HM | 12 wk | 536 | No | 170 | 153 | 17 | 198/536 (37%) | 65/170 (38%) | 62/153 (40%) | 3/17 (18%) |
| Sanchez-Pina et al[58], 2020 | Spain | HM | 1 mo | 39 | 53 | 12 | NR | NR | 14/39 (36%) | 2/12 (14%) | NR | NR |
| van Doesum et al[59], 2020 | Europe | HM | 9 wk | 59 | No | 17 | 15 | 2 | NR | NR | NR | NR |
| Yigenoglu et al[29], 2021 | Turkey | HM | 15 wk | 740 | 188897 | 250 | 223 | 27 | 103/740 (14%) | 28/250 (11%) | 24/223 (11%) | 4/27 (14%) |
| Wood et al[35], 2020 | Worldwide | HM | 3 mo | 250 | No | 79 | 68 | 11 | 70/250 (28%) | 20/79 (25%) | 16/68 (24%) | 4/11 (36%) |
| Lymphoma studies | ||||||||||||
| Regalado-Artamendi et al[40], 2021 | Spain | Lymphoma | 12 wk | 177 | No | 177 | 158 | 9 | 61/177 (29%) | 61/177 (29%) | NR | NR |
| Lamure et al[39], 2020 | France | Lymphoma | 8 wk | 89 | No | 89 | 84 | 5 | 30/85 (34%) | 30/85 (35%) | 29/84 (34%) | 1/5 (20%) |
| Laurenge et al[60], 2021 | France | PCNSL | 2 mo | 13 | No | 13 | 13 | / | 3/13 (23%) | 3/13 (23%) | 3/13 (23%) | |
COVID-19: Coronavirus disease 2019; HM: Hematologic malignancy; HL: Hodgkin lymphoma; NHL: Non-Hodgkin lymphoma; NR: Not reported; PCNSL: Primary central nervous system lymphoma; pts: Patients; UK: United Kingdom; USA: United States of America.